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Molar ratios of therapeutic water-soluble
phenothiazine$water-insoluble phospholipid
adducts reveal a Fibonacci correlation and a
putative link for structure–activity relationships
Hendrik Keyzer,†‡a Stephen J. Fey,‡b Barry Thorntonc and Jette E. Kristiansen*d
The fact that non-antibiotics can sensitise microorganisms for antibiotic treatment suggests that these
molecules have valuable potential to treat multiple drug resistance. Here, we explore the spatial
interaction of selected therapeutic phenothiazine hydrochloride derivatives (PTH) with various lipids.
Micro-gravimetric titrations were performed on aqueous suspensions of promethazine (PMTZ),
promazine (PMZ), triﬂupromazine (TFM), chlorpromazine (CPZ), prochlorperazine$HCl (PClP$HCl),
triﬂuoperazine$HCl (TFP$HCl), prochlorperazine$2HC1 (PClP$2HCl), triﬂuoperazine$2HCl (TFP$2HCl) and
synthetic 1,2diacyl-sn-glycero-3-phospholipids (PL) with even-numbered symmetric saturated diacyl
chains with the headgroups choline (PC), glycerol (PG), serine (PS), ethanolamine (PE), phosphatidic acid
(PA). We observed water soluble products with replicable molar ratios (MR) that could be divided into
two series. ‘Series 1’ (PMTZ < PMZ < CPZ < PClP < TFP) followed the ionization potential and
concomitant sedative eﬀects. ‘Series 2’ followed the lipophilicity of PL and could be related to various
non-neuronal physiological aspects. The MR of Series 2 followed the PL order PC < PG < PS < PE < PA,
echoing the changes in the membrane proportions found in eukaryotic cells proceeding from the
plasma membrane to the endoplasmic reticulum. The same order was found when hydrogen ion
concentration was increased [DiH
+] when plotted against the MR for each separate diacyl series. The
[DiH
+] of the PTH/PL was always larger than that of the self-associated pure PTH. In summary, the
reproducibility and similarity of the measurements using diﬀerent PTH derivatives and PL suggests that
similar adducts are formed in all the cases. We propose that the PTH$PL adduct has a “helical shape”
showing Fibonacci properties for molecules. These observations may open new opportunities for the
development of novel therapies.
Introduction
Chlorpromazine hydrochloride (CPZ) and related exobiotic,
amphipathic, micelle-forming phenothiazine (PTH) salts
(see Fig. 1A for representatives) have shown therapeutic eﬀec-
tiveness against deleterious micro-organisms and cancer
cells.1–6 Evidence is mounting that alone or as helper
compounds, they may revive the use of older, classical antibi-
otics to combat the alarming rise of multi-resistant microbes
world-wide.1,5,7,8 PTH, as neuroleptics, involve stereospecic
sites, but their mode of action includes so-called “non-
neuronal” interactions that may cover many side-eﬀects and
contribute to other psychotropic and/or biological activity.9–12
Human toxicity, oen a concern with PTHs, can be measured in
vitro using 3D cultures, which accurately reect the in vivo
response.13 A truism exists that the longer a drug is in use, the
more side-eﬀects are discovered. Aer all, micro-organisms
have none of the above-mentioned receptors yet become
“sedated” or otherwise react to PTH medicinal intervention.14–16
Goosey and Doggett pointed out that PTH neuroleptics involve
lipophilicity rather than solely shape-specic mechanisms.17
The notion that the PTH accumulates in membranes hetero-
geneously is well-established.18,19 Such amphipaths distribute
into rich and poor domains in phospholipid (PL)
multilayers.20–22 For example, similar activity has been noted for
alamethacin, which forms micelles in aqueous solutions and
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readily incorporates into plasma bilayers, forming channels by
self-association.23 The critical micelle concentration of CPZ in
water is about 105 M.20 With a preference for lipids, cell lysis
begins to occur at 3 105 M.22Membrane saturationmay be as
high as 1 M.20,22 Maher and Singer showed that small
amphipaths, including CPZ, at concentrations lower than those
inducing lysis, promoted gross distribution of components in
the plane of quite diﬀerent membranes, and that this resulted
in their highly selective extraction.22 CPZ tends to accumulate in
humans mainly in lecithin-rich sites, persisting unchanged for
up to 1 year.20,22,24 PL are well-known to move in a cellular
membrane25,26 but the accumulation of PTH at a target PL site,
as one would expect from a PTH-enriched domain, may well
immobilize the PL (sedate), extract it (inducing lysis), penetrate
into, or otherwise disrupt its behaviour in the membrane. Carey
and coworkers showed that CPZ$HCl solubilized membrane
PL eﬃciently as micellar solutions when the drug/PL molar
ratio reached 4 : 1.27 We found a similar eﬀect with phosphati-
dylcholine (PC), phosphatidyl glycerol (PG) and an exobiotic,
synthetic lipid, discovering in the process, that the molar
Fig. 1 (A) Therapeutic psychometric phenothiazine hydrochloride derivatives (PTH) used in this study. (B) PTH Geometry. General headgroup
structure illustrating the tilt angle induced by the diﬀerence in size of the S and N atoms. Diagram of the ‘fold angle’ between the two benzene
rings induced by the S and N atoms and the separation distance between the two PTHmolecules. (C) Diagram of the proposed helical interaction
between the phospholipid (in grey) and the PTH (black). HG ¼ head group, a  u the ﬁrst and last carbon molecules in the acyl tails.
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solubilization of PL by PTH was quite reproducible.28 Therefore,
we examined the eﬀects of various quantities of aqueous PTH
in vitro on some major PL groups found in most eukaryotic and
prokaryotic membranes. We also examined some putative
structure–activity relationships (SAR) other than neurolepticity
and propose higher order structures for the PTH/PL
interactions.
Results
The molar ratios (MR) in Table 1 are generally averages of
triplicates. All PTH/PL interaction product MRs were replicable
to within 5%. The use of hydrochloride salts was justied: for
example, PCLP as the hydrochloride has a PTH/PL MR compa-
rable to that of the edysilate derivative but the maleate deriva-
tive yielded an immediate dense precipitate resisting all further
additions of PTH to reach an MR. The adducts were generally
stable, i.e., did not precipitate until the MR increased for the
most part beyond about 40–50 at which point the initially
soluble adducts tended to precipitate aer 2 to 24 hours,
(precipitation is indicated by the underlined values in Table 1)
probably due to splaying of the longer chains. Above the PL 18C,
MR endpoint errors generally tended to increase.
Fig. 2 shown a plot with error bars of CPZ/PL MR vs.
PL molecular weight (MW). The replicability of the MR data
suggested that the PTH/PL products may well be designated as
adducts rather than by the looser term aggregates, especially in
view of the notion that we may not just be dealing with micelles
per se. Advisedly, and henceforth, we eschew the term “micelle”
wherever possible.29 More evident from Table 1 than from Fig. 2
is that the CPZ/PL adduct MR for comparative Ci (carbon atoms
per chain) always increases in the headgroup order,
PC < PG < PS < PE < PA. All PTH/PL adducts exhibited similar
proles. Thus, we believe that similar conformational struc-
tures are involved. Table 1 shows the MR of various PTH
sequestering PL (C16), and extracts. For the pure PL involved,
on the whole, all the PTH/PL MR followed the same trend:
PMTZ > PMZ > CPZ > TFM > PClP > TFP, including PI, and
E. coli B. Because the characteristic charge transfer complex
adduct colours were observed, especially for the extracts,
developing slowly and deepening upon cooling to 0 C, we
concluded that the PTH in their adducts followed excimeric
charge transfer complex regimes, as they do in the pure form.20
However, charge transfer is conned to the PTH molecules. We
found that this phenomenon extended to all the analogues of
CPZ in our study, and suggested a universal trait.30
Solid state aspects
Tehrani and coworkers claimed to have observed CPZ nano-
crystallites in solution, where the aggregate sizes increased with
increasing concentration, conrming the stepwise CPZ aggre-
gation.31 Barbosa et al. who used small-angle X-ray scattering
and EPR spectroscopy also inferred that CPZ remained in
Table 1 Molar Ratio (MR) for phenothiazine:lipid extracts. * “Series 1” reads horizontally and “Series 2” reads vertically. ** Extract compositions
from Avanti Polar Lipids, Inc. Catalogue VI. Revised. PI: phosphatidylinositol (MW 587): weight%; 33, 16 : 0 saturated; 46.8, 18 : 2 unsaturated.
ESM: egg sphingomyelin: area% FAME-GC/Fl; 16 : 0, 83.9; 18 : 0, 6.3; 20 : 0, 3.8; 24 : 0, 4.2. BSM: brain sphignomyelin: “%”: 16 : 0, 1.7; 18 : 0,
45.5; 20 : 0, 5.1; 22 : 0 7.2; 24 : 0, 23.3. Other unsaturated/undetermined. Bold and underlined values indicate that precipitation ensues after 2–
24 h at MR. E. coli B, total extract: weight%; PE 57.5; PG 16.6; CaL (cardiolipin) 9.8, other 17.6, E. coli B, polar extract: weight%; PE 67, PG2 3.2, CaL
9.8, other 0. Adduct colour of extracts are blue for PMTZ and pink for all the others. Apparent mol. weight of E. coli taken arbitrarily as 750/mol
being the rough average of equimolar PE14 and PG18. Other mol. weights as given by Avanti
MR PTH/lipids* PMTZ$HCl PMTZ$HCl CPZ$HCl TFM$HCl PCIP$2HCl TFP$2HCl TFP$HCl
16 : 0 PC 38.8 22.4 3.8 20.9 11.6 27.7 22.5
16 : 0 PG 49 29.1 9.5 25.8 30.6 56.5
16 : 0 PS 66 33.3 22.2 32.1 85
16 : 0 PE 76 61 29.1 77 112
16 : 0 PA 169 46.6 317 143
PI** 49 37 13 16 18
BSM** 3.8
ESM** 3.2
E. coli B total** 127 86 22 87 145
E. coli B polar** 88 83 18 35 129
Fig. 2 Plot of the total molecular weight of the phospholipid against
the molar ratio PTH/PL for the phospholipids with diﬀerent chain
lengths as given in Table 2 with the following headgroups: - phos-
phatidylphosphate (PA); : phosphatidylethanolamine (PE); C
phosphatidylserine (PS);A phosphatidyl glycerol (PG, chain lengths);
and; phosphatidylcholine (PC). The range of acyl chain lengths used
in all cases was 6–18 except for PC where it was 4–24 (n ¼ 3).
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solution as nanocrystallites.32 We believe that for PTH and
analogues to aggregate in solution stepwise implies heterocycle
to heterocycle interactions, i.e. by excimerization, as conrmed
by Mukerjee and Gosh, for the self-association of methylene
blue into multimers33 (Fig. 1B). PTH side chains serve to
stabilize aggregation via solvent enforcement.31 At the nano-
structural levels, CPZ in solution answers to the demands of
solid state characteristics.20,32,34
Impurity centres
In aggregates of PTH, intermolecular charge transfer complex-
ing is a way of aiding electron delocalization, just as the addi-
tion of a foreign molecule as an impurity centre does.20,34,35 We
regard the PL as such an impurity centre. An aggregate structure
of this kind makes a considerable contribution to the free
energy of the system. At 300 K, this free energy gain is about
0.055 log N eV. In a monolayer of just 20 molecules, the energy
gain is quite substantial, about 0.072 eV. cf., the approximate
hydrogen bond value of 0.08 eV in bulk water.20 The clearest
feature of an excimeric charge transfer complex is the revers-
ibility of equilibrium with its isolated components, according to
the reaction scheme (second and third step) in eqn (1)
(from (ref. 20)):
D (donor) + A (acceptor)5 DA (contact CT)5
DA✸ (exiplex or excimer)5 D+  A5 D+ + A (1)
for an excimer D✸ ¼ A✸.
The energy diﬀerences involved in such excitation processes
are generally small, in the order of kT, and can therefore be
produced by a variety of supplying mechanisms, (including
electrochemical phenomena at membrane surfaces),36,37 with
profound consequences for electron transfer processes in the
presence of PTH.20 For high stability, charge transfer should be
incomplete.38 Excimeric electron aﬃnity is increased if the
electron is taken not to the bottom of the conduction band but
into an excited state energy level leading to enhanced
complexation. If the electron is raised not from the Fermi level
but from a higher excited state energy level, the ionization
potential is reduced leading again to enhanced complexation.
Both processes can occur simultaneously. Excimeric charge
transfer complexes play important roles in many biological
processes.20 A corollary of aqueous assemblages of such parti-
cles is that counter-ions and water molecules are attracted by
the hydrophilic regions, and assume extensively ordered states.
Excitation also leads to considerable changes in magnitude and
direction of the dipole moments.39,40
pH eﬀects
Self-association of PTH reduces the pH of the cationic drug
assembly, such as that seen for PMZ, CPZ and thioridazine
(TDZ).29,41,42 Furthermore, all PTH/PL adducts were more acidic
in PTH concentrations equivalent to the pure drugs. The
straight line plots in Fig. 3, in which the hydrogen ion
concentration diﬀerences ([DiH
+]) vs. MR show a regular
increase, is evidence that the PTH/PL adducts have specic, and
similar, structures (denition: [DiH
+] ¼ [H+]PTH/PL  [H+]PTHpure
at equimolar PTH concentrations). Within the cohorts of PL,
with diﬀerent headgroup but the same Ci, the plots for the
smaller Ci show concomitant smaller [DiH
+] increases, as
exemplied in Fig. 3. This gure shows that [DiH
+] is strongly
dependent on the acyl chains. The [DiH
+] increase with
increasing MR indicates that the protonated side-chains of the
adduct PTH molecules orient away from the hydrophobic PTH/
PL core, and thus structure the immediately adjacent (vicinal)
water environment and by extension, lower the pH of the bulk
solution. Water-assisted aggregation forces the PTH molecules
into higher-order ion clusters, and increases the dielectric
environment; hence, forcing the proximity of the heterocyclic
ring donor and ring acceptor groups. This is expected to
strengthen charge transfer excimerization.20 The PL acyl chains
are then also forced into closer proximity by the hydrophobic
PTH ring assemblies. The plots indicated that the diﬀerent PL
headgroup interacted with the PTH in a closely similar manner,
irrespective of whether the PL were zwitterionic or salts. Note
that the points on each line in Fig. 3 again follow the PL MR
hierarchy, as shown in Fig. 2 (PS > PE > PA).
Inuence of the headgroup
Yeagle claimed that the PL headgroup and acyl chains may be
treated as being partially independent of motion and may thus
be treated separately.43 In terms of imbibing water, i.e., water
binding, eggPE < eggPS < eggPC, follows the hierarchy of CPZ/
PL MR vs. PL MW44,45 (Fig. 2). A single methyl group added to
PE (PE Me) sees a 28% increase in hydration while successive
methylations increase the hydration by 7% and 16%, respec-
tively.46,47 Such hydration increases are also seen for successive
methylations of dioctanoyl-PE and dimyristoyl-PE.48–50 We thus
infer that full PL hydration is observed in all our experiments.
The solubility of the PL as a function of the headgroup plays a
Fig. 3 Plot of the diﬀerences in the hydrogen ion concentration ([DiH
+])
between pure PTH and the PTH/PL adduct plotted against the molar
ratios (MR) of three diﬀerent classes of PTH, where the classes have the
same head group but diﬀerent phospholipid chain lengths (PL)- C18
phosphatidylphosphate PA, R2 ¼ 0.97; : C16 phosphatidylethanol-
amine PE, R2 ¼ 0.99;C C14 phosphatidylserine PS, R2 ¼ 0.92 (n ¼ 3).
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major part in the MR hierarchy shown in Fig. 2. PC is the most
soluble of the groups in Fig. 2 and phosphatidic acid (PA) the
least, reected in increasing MR according to the adducts with
the same diacyl chains in the order PC < PG < PS < PE < PA. Not
only is solubility a factor but the adducts of PL with larger
headgroup volume have smaller [DiH
+] (Fig. 3). All the PTH/PL
interactions exhibit similar [DiH
+] changes. This suggests that
the initial site of adduct formation is situated nearer the a part
of the diacyl chains than the headgroup (Fig. 1C). A larger
dynamic headgroup as well would provide more steric
hindrance to the initial PTH anchoring site. This is seen for the
series in Fig. 4, in which the headgroup size increases by virtue
of methyl additions 16PE < 16PENMe < 16PEN2Me < 16PC
whose MR fall on the 16PL line in Fig. 3, and concomitantly
exhibit smaller [DiH
+] in that order.
Inuence of the diacyl chains
Fig. 2 and 3 show unambiguously that longer diacyl chains elicit
larger PTH/PL MR. Considering the steric hindrance of the
headgroup, the MR for PTH/PL is an index of the lipophilicity of
the PL in question. Thus, for example, PA, the most lipophilic of
the PL in our experiments, must acquire a larger quantity of PTH
for its adducts to become water-soluble, as indeed is observed.
This phenomenon may be explained by placing the lipophilic
portion of the PTH nearer to the initial anchoring site of PA
namely at a in its diacyl chains (Fig. 1C). Further, to render the
adduct soluble, more PTH has to be marshalled to that site. In
turn, as the length of the diacyl chains is increased, the PTH
excimeric ribbon must be extended to cope with the increasing
lipophilicity of the PL until a point is reached where the splay and
motion of the diacyl chains overcomes the cohesive excimeric
and the vicinal water structure energetic regimes that keep the
adducts soluble. This usually occurs when an MR of about 40 to
50 is reached. This view explains why the adduct of CPZ/24PC
(MR 53) CPZ/18PS (MR 38) and CPZ/16PE (MR 46) precipitate
overnight, while CPZ/18PA (MR 78) precipitates within several
hours (see the bold MR values in Tables 2A and 2B).
Sedative eﬀects
Some workers claimed that the sedative eﬀect of clinical doses
of psychotropes for stereospecic site interaction increased in
the order, PMTZ < PMZ < CPZ < PClP < TFP (“Series 1” rst row
in Table 1).51,52 The PTH charge transfer complex order depends
on the electron withdrawing power of the substituent in the
heterocyclic 2-position, –CF3 > –Cl > –H, with the consequent
increasing ionization potential (Ip)53,54 as well as exibility of the
molecules.52 Fulton and Lyons suggested that the increasingly
sedative eﬀect of PTHs tended to follow their decreasing ioni-
zation potential Ip.47 However, they emphasised caution in this
respect, because there was little diﬀerence between the tran-
quilizers and stimulants. A smaller Ip allows the easier loss of an
electron in a charge transfer event. However, it is necessary to
consider that charge transfer in an excimer context is a proba-
bility process, in which the electron may not actually be lost by
the donor but may spend more time near the acceptor. Thus,
physiological activity does not depend on the electron donor
power alone. Conformational factors and the lipophilicity-
inuencing activity of psychomimetic drugs has been dis-
cussed extensively.9,55–58
Fig. 4 Plot of the diﬀerences in the hydrogen ion concentration
([DiH
+]) versus the number of methyl groups for C16 phosphatidyl-
choline; R2 ¼ 0.98 (n ¼ 3).
Table 2 (A) MR of PTZ/PL combinations and (B) their diﬀerences with
increasing acyl chain length. Bold and underlined values indicate that
precipitation ensues after 2–24 h at MR. Note that equal diﬀerences
tend to fall on a diagonal (see for example the values in bold type)
A Molar ratio (MR)
CL/MR PC PG PS PE PA
4 0.27
6 0.8 2.1 2.5 4.2 4.6
8 1.3 2.3 4 4.9 6.4
10 1.5 4.3 5 9.3 10
12 1.9 4.3 7.2 10.4 17.8
14 2.6 7.2 10.5 17.8 30.1
16 3.8 9.5 22.2 29.1 45.6
18 6.7 16.1 38.1 46.5 78
20 12
22 26.7
24 53
16PE-NMe 14.8
16PE-NMe2 5.5
B
Molar ratio diﬀerences with increasing
acyl chain length (DMR)
CL/MR CL (average) PC PG PS PE PA
6–4 5 0.53
8–6 7 0.5 0.2 1.5 0.7 1.8
10–8 9 0.2 2 1 4.4 3.6
12–10 11 0.4 0 2.2 1.1 7.8
14–12 13 0.7 2.9 3.3 7.4 12.3
16–14 15 1.2 2.3 11.7 11.3 15.5
18–16 17 2.9 6.6 15.9 17.4 32.4
20–18 19 5.3
22–20 21 14.7
24–22 23 26.3
Partial sum DMR for
(8–18)
5.9 14 35.6 42.3 73.4
This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 5, 20865–20877 | 20869
Paper RSC Advances
Non-neuronal eﬀects
Our MR data is at odds with the sedative clinical information
above and may indicate non-neuronal aspects. The PTH
aromatic rings are capable only of buttery wing motion about
the N–S axis, rarely if ever inverting, whereas the side-chains are
exible depending on the length and substituents. When
conformational factors of the PTH in its PL adducts are exam-
ined, their correlation with the MR becomes evident. This is
PC < PG < PS < PE < PA and referred to as “Series 2” (Table 1, rst
column). While Series 2 is concerned with the PTH/PL adducts
only, this leads to a possible insight into other clinical eﬀects.
PMTZ has a methyl substituted in the two-carbon side-chain
and will have a less exible side-chain. PMZ, CPZ and TFM
share a simple propylamine side-chain. While the strength of
the electron withdrawing groups in the ring 2-position plays an
important role, the sizes of those groups also increase in the
order, H < Cl < CF3, inducing a steric hindrance eﬀect that may
aﬀect excimerization. The perazines have a piperazinyl side-
chain that is longer than the simple propylamine group.
Moreover, the piperazinyl group introduces two quatemizable
N atoms, leading to boat or chair conformations depending on
whether one or both are protonated.58 The perazine boat form
(mono-H+) is preferred at a pH of approximately 5, i.e., within
the conventional clinical range of PTH with a propylamine side-
chain. The di-protonated piperazinyl chair form exists in the
pH range of about 3.58 Table 1 shows that TFP$HCI (boat form)
has a considerably lower MR than the chair form TFP$2HCl for
16PC, indeed invariably so for all TFP/PC adducts with corre-
sponding Ci tested. There is no doubt that this phenomenon
involves vicinal water, which is less structured for the chair than
the boat form. We suggest that the psychomimetic eﬀect follows
Series 1 until the available stereo-specic sites are occupied or
even saturated, aer which the unused excess PTH are exposed
to PL in non-neuronal terms (i.e. in “Series 2” order Table 1:
PC > PG > PS > PE > PA). Thus the process for self-associated
PTH accumulation at membranes has several avenues avail-
able for interaction. The tertiary PTH interaction is mainly at
the intrinsic proteins; quatemized PTH interacts only with
phospholipids.59 The relatively distinct sets of physiological
action can now be ascribed to one series (Series 1) involved with
neurolepticity requiring a specic conformation of a single PTH
at a stereoselective protein site, and to another (Series 2) with a
much more generalized interaction of a PTH pseudopolymer at
the available membrane PL sites. The overlap of Series 1 and 2 is
yet to be determined.
Putative PTH/PL structure
The conventional view of amphipathic PTH aggregates being
spheroidal, ellipsoidal, cylindrical or disc-shaped may not apply
in our case.60 A recent study of the self-assembly of PTH
compounds was inconclusive with respect to the assignment of
three-dimensional models: ellipsoids, cylinders or parallelepi-
peds.32 Although at low concentrations, the aggregate structure
may approximate the Hartley spherical model, this is unlikely to
prevail inmore concentrated solutions, as conrmed by streaming
double refraction and X-ray diﬀraction measurements.32 In the
mixed PTH/PL systems, diﬀerent three-dimensional criteria are
likely to come into play, as has been observed with aggregates of
PL and other ionic and non-ionic surfactants. See for example
the work of Almgren, who observed lace-like or thread-like
structures for CPZ without intermediates in the form of
disks.61 Zuchowski and Durand showed that cationic PTH
amphipaths interact with articial and biological membranes
so that aer the amphipath enters the membrane, a new type of
interaction occurred.62 Zhao's group, working with paclitaxel
(an anticancer compound with an ionisable tertiary N group),
showed that incorporation of the drug into PL models diﬀered
according to the headgroups, alky 1 chain lengths and
unsaturation.63–65
Recently, Kopec and Khandelia carried out some computer-
assisted predictions of the interactions between the anti-
tuberculosis candidate drug thioridazine and two diﬀerent
model bilayers a zwitterionic POPC (1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine) and a negatively charged,mixed POPC/
POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine).66 They
have made a number of predictions that were coherent with the
ideas presented here. Firstly, they proposed that the positively
charged protonated amino group of THZ's piperidine ring
interacts with both the lipid headgroup and the glycerol back-
bone region via electrostatic interactions (salt bridges) and/or
hydrogen bonds similar to that illustrated in Fig. 1C.
Secondly, they predicted that the preferential orientation of the
molecule with the phenothiazine ring was placed almost
perpendicularly to the bilayer, as seen in Fig. 1C. They also
noted that this is the preferred orientation of cholesterol.67
Finally, they reported that the strong interaction of the piperi-
dine ring with the lipid phosphate group and glycerol back-
bone, will limit the conformational possibilities of the aromatic
tricycle, making a parallel alignment highly unfavourable. This
is in agreement with the hypothesis proposed here, where the
aromatic tricyclic rings are only partially overlapped. This, the
fold and the tilt angle (Fig. 1B) will provide separation in three
dimensions for the piperidine ring.
Phospholipid splay angles
If one considers for simplicity the PTH to be arranged in
circular rings, then by calculating the diﬀerence between the
MR for increasing Ci steps, then one can obtain a rough esti-
mate of the number of CPZ molecules that bind to the
additional chain length of the PL (Table 3). Knowing this, one
can calculate the fold angle around the S–N axis (Fig. 1B).
In geometric algebra terms, the sequence of numbers in
Table 3 can be considered a source for providing progressive
values of 2D orthogonal projections of molecular locations on
the spiral pathway onto a at surface, the values of which
determine the splay angle and pitch of the spiral (cf. an inverse
problem in mathematics or time consuming analysis).
Assuming the CPZ excimer to be fully overlapped then the
length Q (Fig. 1B) can be used to calculate the eﬀective length of
the sides of the polygon descried by the PTH molecules. The
absolute length for Q varies from about 2.75 to 3.25 A˚ depending
on which source is used (CSR space lling or ChemDraw models
20870 | RSC Adv., 2015, 5, 20865–20877 This journal is © The Royal Society of Chemistry 2015
RSC Advances Paper
of various PTH derivatives). Its absolute length will be reduced to
an eﬀective length because of the fold and the thickness of the
carbon ring. An absolute length of 3 A˚ is used for the calculations
presented in Table 3 (although other values in the 2.75–3.25 A˚
range do not result in signicantly diﬀerent conclusions). Once
the length of the polygon edge formed by the CPZ is known, it is
possible to calculate the radius of the inscribed circle. Yeagle
(Chapter 1, Tables 1–7) gave the cross-sectional areas of several
diﬀerent phospholipid chains, which can be used to provide an
averaged area of 38.05 A˚2.43 Using the radius of the phospholipid
chain thus to be 3.48 A˚, it is then possible to calculate the splay
angle of the phospholipid chains. Once again it is possible to see
that the Series 2 order is maintained (PC < PE < PA) when the
splay angle is compared with the chain length (Fig. 5).
Returning to the spiral concept presented in Fig. 1C, it would
appear that at longer chain lengths, due to the splay angle of the
phospholipid chains, that the spiral is in fact some sort of helix
(Fig. 6). This could be anticipated considering the tilt and fold
angles of the PTH molecule. From the available data, it is not
possible for us to decide whether the helix has one or more
threads around the central phospholipid chains and so Table 3
gives the splay angles for a single or two threads as examples.
One well-known series of numbers, oen associated with a
spiral in nature, is the Fibonacci series (1, 1, 2, 3, 5, 8, 13, 21, 34,
55.) as seen in the seeds on a sunower, the spirals of shells,
and the curve of waves. In theoretical studies in the mathematics
of fractals for constructions using triangles (in 2D), the results
show that the Fibonacci sequences can be found in the gaps
formed.68 Here it is interesting to note that if the molar ratios
determined here for all ve PTH (PC, PG, PS, PE and PA) are
plotted against this series, then one obtains straight line graphs
with a correlation coeﬃcient greater than 0.987 in all cases
(Fig. 7). Its signicance was unclear until it was recognised as
being related to energy optimisation in 3D, such as in some
nature examples (e.g. spinal growth in some plant locations along
a stem), However, this is one of the rst observations of the
Fibonacci series tting at the molecular level.
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Fig. 5 Plot of the splay angle versus the chain length for - phos-
phatidylphosphate (PA, R2 ¼ 0.96); : phosphatidylethanolamine
(PE, R2 ¼ 0.99); and ; phosphatidylcholine (PC, R2 ¼ 0.99) (n ¼ 3)
calculated as shown in Table 3.
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Correspondence of PTH/PL and PL
In terms of cellular biosynthetic routes (precursor/ product):
PA/ PG, PA/ PI, PA/ PS/ PE/ PENMe/ PEN2Me/
PC / SM,69–71 it is remarkable that product PTH/PL MR is
almost always smaller than that of the precursor PTH/PL MR
(the exception being PS/ PE); see Table 1 and Fig. 2. The MR
indicates that fewer PTH molecules are used to enclose (and
modify the properties of) PA than PS.
It has long been appreciated that lipid species are not
distributed equally among the various cellular membranes72,73
and that the membrane itself is asymmetric and has substruc-
tures including ras.74 In the outer leaet in bacteria, aer
closely bound PE and cardiolipin (CL), the third major PL is PG.
van Meer, Voelker and Feigensohn produced an elegant article
on the location, prevalence and distribution of PL within a
eukaryotic cell.74 In terms of concentration and traversing the
cell from the outer cell membrane to the ‘core’ (endoplasmic
reticulum and mitochondria) of the cytosol, the PL distribution
tends to follow the Series 2 order, i.e. PC > PG > PS > PE > PA.22,74
Interestingly, PE, and PS are located preferentially on the cyto-
solic side of the plasma membrane, whereas sphingomyelin
(SM) is located predominantly in the outer layer (luminal side)
of the plasma membrane. This gradation results in inner
membranes being loosely packed while the outer membranes
are stiﬀer and closer to adopting a ‘solid’ gel phase.
Therefore, the PL most protected from external assault
(treatment) by the PTH in eukaryotic cells is PA, which is also
the precursor of ultimately all the PL products mentioned
above. The next are PE, and PS. Thus, the most PTH ‘sensitive’
PL are the PL that are the most protected and the least sensitive
are the most exposed. This may well have important conse-
quences for PTH treatments.
Tumour cells produce extra PG and PC, and this apparently
contributes to both proliferative growth and programmed cell
death mechanisms.75 PC, sphingomyelin (SM) and PG have also
been found in higher proportions in various cancer cells.76 This
may be present convenient targets for interaction with PTH.
Children with frequently recurring pyelonephritis responded
better to combined PMTZ/antibiotic treatments than to antibi-
otics alone; and no new renal scarring was observed in the
PMTZ-tested group.20 Free oating E. coli are likely destroyed
Fig. 7 Plot of the molar ratio of PTH/PL for the phospholipids with diﬀerent chain lengths against the Fibonacci numbers from 3 to 55.
Headgroups:- phosphatidylphosphate (PA, R2 ¼ 0.99);: phosphatidylethanolamine (PE, R2 ¼ 0.99);C phosphatidylserine (PS, R2 ¼ 0.98);A
phosphatidyl glycerol (PG, R2 ¼ 0.98); and; phosphatidylcholine (PC, R2 ¼ 0.98). The range of acyl chain lengths used in all cases was 6–18.
Fig. 6 The key deﬁnitions for a helix. a ¼ splay angle; p ¼ pitch;
R¼ radius and q circumferential angle.
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rst, while the adherent pathogens are more tenacious because
less surface area is exposed, PTH/PG still being involved.
Discussion
If the PTH forms spiral metastructures around phospholipids,
what would be the eﬀects and consequences?
Considering the PTH molecule itself, the hydrophobic ring
structures are reasonably at and thus would presumably
tolerate a reasonable amount of relative rotational movement.
This would allow the variable pitch in the spiral needed for
diﬀerent splay angles (SA and p in Fig. 7 respectively).
While one would anticipate that the fold angle (Fig. 1B)
would be quite inexible, the eﬀective fold angle may actually
be augmented by allowing the hydrophobic ring structures to
rock on each other. This is probably necessary to achieve the
range in number of PTH molecules in the rings/spirals around
the phospholipid (as given in Table 3 column ‘d’).
The resolution of the molar ratios into straight lines by
plotting them against the Fibonacci series is especially
intriguing. This is interesting regarding Fibonacci numbers and
the coverage of special sections. The generating function f(x) of
the Fibonacci numbers satises the identity:
(1  x  x2)f(x) ¼ x
which leads to the closed form
tn  (1  tn)/O5
where
t ¼ (1 + O5)/2 (2)
This is the so-called ‘golden-mean’ (or ‘golden ratio’) of
identical copies of a fundamental structural unit cell oriented in
the same way. This again suggests a highly ordered alignment of
the PTH molecules around a central point.
The splay of the phospholipid itself induced by the PTH
molecule would lead to a local membrane thinning and changes
in membrane uidity and functionality. Membrane thinning
and expansion has been observed in other biological situations,
including binding to antimicrobial peptides and to PTH.66
Antimicrobial peptides have been shown to produce perturba-
tions of the phospholipidmembrane by the formation of specic
lipid–peptide domains, lateral phase segregation of zwitterionic
from anionic phospholipids and even non-lamellar lipid pha-
ses.77 Furthermore, some peptides change their topology in a pH
dependent manner and these peptides have been shown to be
more potent in antibiotic assays under experimental conditions,
where they show approximately in-plane alignments.78 In an
interesting study using four of the phospholipids used here (PC,
PG, PS and PE), Sevcsik et al. reported that their interaction with
the humanmultifunctional peptide LL-37 shows that net charge
of the lipid is not the decisive factor determining themembrane-
perturbing mechanism of LL-37. The perturbation is induced by
a combination of several parameters, including the packing
density, the ability to form intermolecular H-bonds, and the
molecular shape of the lipid.79
Fig. 8 Diagram of the key measurements for the splayed phospholipid. (A) Line T indicates the mid-axis between the two acyl chains of the
phospholipid of chain length CL (from a to u). r¼ the circumferential diameter around one acyl chain. R¼ the radius of the bounding circle of the
polygon. (B) Diagram of the relationship among r, R, the polygon and its bounding circle. The polygon and bounding circle are separated for
clarity. (C) Splayed phospholipid. SA is the splay angle and d is the diﬀerence 2R  2r.
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The organisation of the PTHmolecules around a phospholipid
impurity centre would also result in a uniformly charged annulus
(where the actual charge depends upon the individual PTH
molecule in question and the local pH). Without counter ions,
this would be expected to induce a destabilising force between the
individual PTH molecules, but it may also be this force repulsion
that together with hydrophobic attractive forces between the ring
structures and the acyl chains, helps push the PTH molecules
deeper into the lipid bilayer in each successive turn of the helix.
The PTH and phospholipidmolecule ‘complex’will present a
fairly large structure (extending up to approximately 60 A˚ from
Table 3). Such a structure would also be expected to have a
signicant eﬀect on the local membrane curvature strain,
surface charge, uidity, and melting point. This could be the
basis for the observations that triuoperazine forms drug-rich
domains in membranes, which in turn lead to the inhibition
of the outward transport of anticancer drugs by the glycoprotein
P (Pgp) in cancer cells.5,80 Whether the changes in membrane
properties are the result of incomplete miscibility, as suggested
by Cieslik-Boczula et al., or whether it is due to the molecular
organisation suggested here, is yet to be determined.
Depression of the membrane's melting point by anaesthetic
molecules has been known for a long time. Recently, Græsbøll
et al., describedageneralmodel toexplain theanaesthetic features
of arbitrary molecules, in which they proposed that ‘anaesthetics
are ideally soluble in the liquid phase of the membrane only
and are insoluble in the solid phase.81 Such a PTH and phospho-
lipid molecule complex as described here would clearly have
signicantly diﬀerent entropies in the liquid and solid states due
to the ‘accessibility’ of individual phospholipid molecules.
Experimental
Gravimetric micro-titration
We used the simplest preliminary method, gravimetric micro-
titration, to examine the behaviour of the PTH/PL interactions
in water to avoid possible buﬀer or ion-adjusting salts eﬀects,
particularly in view of the fact that PTH behaves as buﬀers in
microclimates. In addition, we conned ourselves to PTH in
hydrochloride form to avoid anionic diﬀerences.52
Reagents
The reagents were used as received. The PTH$hydrochlorides
(Fig. 1A) came from Sigma Chemical Co., and all were innitely
water-soluble for our experimental purpose. Avanti Polar Lipids
supplied the natural product extracts, as well as all the puried
(99% or better), synthetic 1, 2-diacyl-sn-glycero-3 -phospholipids
(PL) with diﬀerent headgroups (HG), and with even-numbered,
symmetric, saturated diacyl chains varying generally from 8 to
24 carbon atomsper chain. Such numbers are indicated variously
as iC or Ci, e.g., 16PL or C16. The PL headgroups were choline
(PC), ethanolamine (PE), the mono-sodium salts of phosphate
(PA), rac-1-glycerol (PG), and L-serine (PS). The other PL were 16
-methyl-substitutedPE (16PEMe, 16PE2Me).Thenatural product
extracts were Eschericia coli B, egg- and brain-sphingomyelin,
(ESM) and (BSM) respectively, and phosphatidyl inositol
(PI). The PL molar weights may be found in the Avanti Products
Catalogue Revised VI (homepage, http://www.avantilipids.com),
which also gives extract compositions used here.
Equipment
Denver A200DS balance (105 g), Oakton 1000 pH meter (0.01),
(6 mm) Accumet pH electrode, Haake circulating pumps, Cole-
Parmer 8848 ultrasonic bath, silanized microsyringes, 15 mL
silanized glass vials with Bakelite screw-caps, the latter never in
contact with mixtures and solutions. The silanization product
was Dow Coming MDX4-4159 Fluid provided by Factor II, Inc.
P.O. Box 1339, Lakeside, Arizona 85929. The vials were silanized
to obviate the negative surface charge on glass, also found on
membranes and vesicular surfaces that could aﬀect the course
of PTH/PL aggregation.20,35
Procedure
Water was added to accurately weighed PL powder (in the range
of 1–3 mg) yielding ultimately 105 M, (i.e., within an order of
magnitude of the 106 M critical micelle concentration (CMC)
of biological PL, most of which have two long acyl chains17).
Moreover, the PL were fully hydrated (see later). The suspension
was subjected to sonication and heating to several degrees
Celsius beyond the corresponding PL phase transition
temperatures;82 sonicated again at 37 C; cooled to 0 C; again
sonicated at 37 C; and then incubated at 37 C, (each step for
1–3 min). The PTH solution (0.15 M) was added by a micro-
syringe in weighed increments, the mixture was subjected to
the above temperature cycle, and addition and cycling were
repeated until the turbidity cleared, which was taken to be the
adduct endpoint and expressed as the PTH/PLmolar ratio (MR).
The solution was clear in a temperature range of several degrees
Celsius on either side of the MR. Aer each incubation, the vial
and contents were allowed to reach room temperature, upon
which the vial (externally) and cap (internally and externally)
were dried with lintless tissue, and the assembly tared for further
additions of PTH. At room temperature and MR, the pH of the
adduct solutions was compared with that of the equivalent pure
PTH concentration for relatively soluble PL with small iC-
numbers (see Avanti Catalog). Aer the MR had been reached
and the pH taken, the PTH/PL mixtures were stored in the dark
for evaluation of colour production, and possible reprecipitation.
Conclusions
Wehave presented data to illustrate that the interaction products
of PTH and PL are water-soluble and stoichiometric, their molar
ratio (MR) following a dened order of the headgroups (Table 1).
Within this group, phosphatidyl ethanolamine-mono-methyl
(PENMe) and phosphatidyl ethanolamine-di-methyl (PE 2Me)
must be counted. TheMR in vivo interaction products PTH/PLare
always smaller than the PTH/precursor PL. The increase in
hydrogen ion concentration [DiH
+] is always larger for thePTH/PL
than for the equivalent pure PTH concentration [DiH
+], and it is
strongly dependent on the diacyl chain length. Each chain length
inFig. 3 contains all the PTH tested in the abovementionedorder.
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This conrms Yeagle's claim of the partial independence of the
headgroup and the acyl groups of a PL.43
Finally, the reproducibility of the molar ratio suggests that
PTZ and PL interact in a dened matrix as adducts and not as
loose aggregates. Because the results for all the various PTZ
always retained the order of Series 2, this suggests that the
adducts formed are similar in all the cases. Therefore, we used
the molar ratios and knowledge about the forces between the
molecules to propose that a phospholipid can act like an
impurity centre, around which PTZ can form a helix. If the chain
length is suﬃciently long and the headgroup is small, the two
lipid chains can splay to maximise the hydrophobic binding.
The correlation between the molar ratio and the Fibonacci
series suggests that the adducts formed are well organised to
minimise the energy relationships.
A comparison of the data obtained here with the known
therapeutic eﬀects of these derivatives leads to the observation
that the therapeutic phenothiazine derivatives (PTH) can be
divided into two overlapping groups. One of these (referred to
here as Series 1) is psychotropic and based on heterocyclic ioni-
zation potentials. The other (Series 2) is based on lipophilicity
and is related to the non-neuronal eﬀects on cellular membrane
phospholipids, which results in their therapeutic eﬀectiveness
against deleterious micro-organisms and cancer cells.
Abbreviations
CL Chain length
Ip Ionization potential
MR Molar ratio
PL Phospholipid
CPZ Chlorpromazine
PClP$HCl Prochlorperazine$HCl
PClP$2HCl Prochlorperazine$2HC1
PMTZ Promethazine
PMZ Promazine
PTH Phenothiazine hydrochloride derivatives
TFM Triupromazine
TFP$HCl Triuoperazine$HCl
TFP$2HCl Triuoperazine$2HCl
PA Phosphatidate (or phosphatidic acid)
PC Phosphatidylcholine
PE Phosphatidylethanolamine
PENMe PE16Nmethyl
PENMe2 PE16Ndimethyl
PG Phosphatidyl glycerol
PS Phosphatidylserine
CaL Cardiolipin
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